TITLE

Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins

AUTHOR(S)
Bernardo, Lidice; Hermida, Lisset; Martin, Jorge; Alvarez, Mayling; Prado, Irina; López, Carlos; Martínez, Rafael; Rodríguez-Roche, Rosmari; Zulueta, Aida; Lazo, Laura; Rosario, Delfina; Guillén, Gerardo; Guzmán, María G.
PUB. DATE
May 2008
SOURCE
Archives of Virology;May2008, Vol. 153 Issue 5, p849
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The suitability of dengue 2 envelope domain III recombinant fusion proteins [(fusion (PD5) and insertion (PD3) variants)] for inducing functional antibodies and a protective immune response in nonhuman primates has been reported. However, the evaluation of the antibody response after immunization did not correlate with the protection data as measured by viremia detection. Here, we characterized the anamnestic immune response after viral challenge in monkeys immunized with the dengue 2 recombinant proteins in an attempt to define correlates of protection useful for vaccine studies. Monkeys immunized with PD5 (most protected group) exhibited an earlier increase in the anti-DENV-2 IgM response after challenge compared to control animals. Hemagglutination-inhibiting (HAI) antibodies were increased significantly earlier in PD5-immunized animals compared to those immunized with PD3. The fully protected monkeys showed the earliest HAI antibody response. These results underline the usefulness of the anamnestic antibody response for supporting protection data. The induction of an early HAI and IgM antibody response after challenge suggest a protective role against dengue virus (DENV) infection in monkeys, supporting their use as correlates of protection in vaccine studies.
ACCESSION #
31694930

 

Related Articles

  • Recombinant antibodies for environmental analysis. Kramer, K.; Hock, B. // Analytical & Bioanalytical Chemistry;Oct2003, Vol. 377 Issue 3, p417 

    Initial steps of antibody engineering in the late eighties revolutionized the technology of antibody production, particularly in the area of immunotherapy and diagnostics. Hallmarks that seemed to be out of reach for a long time are now the state of the art, e.g. tailoring of antibodies to match...

  • 'Trivalent influenza vaccination of healthy adults 3 years after the onset of swine-origin H1N1 pandemic: restricted immunogenicity of the new A/H1N1v constituent?'. Allwinn, R.; Bickel, M.; Lassmann, C.; Wicker, S.; Friedrichs, I. // Medical Microbiology & Immunology;Apr2013, Vol. 202 Issue 2, p125 

    Influenza vaccination is advised annually to reduce the burden of influenza disease. For sufficient vaccine campaigns also a continuous adoption of influenza vaccines are necessary, due to particularly high genetic variability of influenza A virus. Therefore, we evaluate the effectiveness of the...

  • Immunogenicity of Three Different Influenza Vaccines against Homologous and Heterologous Strains in Nursing Home Elderly Residents. Baldo, Vincenzo; Baldovin, Tatjana; Pellegrini, Michele; Angiolelli, Gabriele; Majori, Silvia; Floreani, Annarosa; Busana, Marta Cecilia; Bertoncello, Chiara; Trivello, Renzo // Clinical & Developmental Immunology;2010, p1 

    We studied whether MF59-adjuvanted influenza vaccine improves immunity against drifted influenza strains in institutionalised elderly with underling chronic health conditions. Sera from a randomized study, comparing MF59-adjuvanted (Sub/MF59, n = 72), virosomal (SVV, n = 39), and split (n = 88)...

  • Serum strain-specific or cross-reactive neuraminidase inhibiting antibodies against pandemic A/California/07/2009(H1N1) influenza in healthy volunteers. Desheva, Yulia A; Smolonogina, Tatiana A.; Donina, Svetlana A.; Rudenko, Larisa G. // BMC Research Notes;2015, Vol. 8 Issue 1, p1 

    Background: Pre-existing antibodies to influenza virus neuraminidase may provide protection against infection influenza viruses containing novel hemagglutinin (HA). The aim of our study was to evaluate serum neuraminidase-inhibiting (NI) antibodies against A/California/07/2009(H1N1)...

  • Elicitation of Neutralizing Antibodies Directed against CD4-Induced Epitope(s) Using a CD4 Mimetic Cross-Linked to a HIV-1 Envelope Glycoprotein. Dey, Antu K.; Burke, Brian; Sun, Yide; Sirokman, Klara; Nandi, Avishek; Hartog, Karin; Lian, Ying; Geonnotti, Anthony R.; Montefiori, David; Franti, Michael; Martin, Gr�goire; Carfi, Andrea; Kessler, Pascal; Martin, Lo�c; Srivastava, Indresh K.; Barnett, Susan W. // PLoS ONE;Jan2012, Vol. 7 Issue 1, p1 

    The identification of HIV-1 envelope glycoprotein (Env) structures that can generate broadly neutralizing antibodies (BNAbs) is pivotal to the development of a successful vaccine against HIV-1 aimed at eliciting effective humoral immune responses. To that end, the production of novel Env...

  • Mouse genetic model for antigen-induced airway manifestations of asthma. Piavaux, B.; Jeurink, P. V.; Groot, P. C.; Hofman, G. A.; Demant, P.; Van Oosterhout, A. J. M. // Genes & Immunity;Jan2007, Vol. 8 Issue 1, p28 

    Allergic asthma is a genetically complex disease characterized by allergen-specific immunoglobulin (Ig)E, eosinophilic inflammation of the lungs and airway hyper-responsiveness to bronchospasmogenic stimuli. In this study, we compared 13 recombinant congenic (RC) mouse strains in an ovalbumin...

  • Elicitation of Neutralizing Antibodies Directed against CD4-Induced Epitope(s) Using a CD4 Mimetic Cross-Linked to a HIV-1 Envelope Glycoprotein. Dey, Antu K.; Burke, Brian; Sun, Yide; Sirokman, Klara; Nandi, Avishek; Hartog, Karin; Lian, Ying; Geonnotti, Anthony R.; Montefiori, David; Franti, Michael; Martin, Grégoire; Carfi, Andrea; Kessler, Pascal; Martin, Loïc; Srivastava, Indresh K.; Barnett, Susan W. // PLoS ONE;Jan2012, Vol. 7 Issue 1, p1 

    The identification of HIV-1 envelope glycoprotein (Env) structures that can generate broadly neutralizing antibodies (BNAbs) is pivotal to the development of a successful vaccine against HIV-1 aimed at eliciting effective humoral immune responses. To that end, the production of novel Env...

  • Virus strain discrimination using recombinant antibodies. N. Boonham; I. Barker // Disease Markers;2000, Vol. 16 Issue 1/2, p95 

    Most routine testing for plant viruses is currently carried out using monoclonal and polyclonal antibodies. Traditional methods of antibody production however can be time consuming and require the use of expensive cell culture facilities. Recombinant antibody technology however is starting to...

  • Antibodies: Validate recombinants too. Freedman, Leonard P. // Nature;2/25/2015, Vol. 518 Issue 7540, p483 

    A letter to the editor is presented in response to an article by A. Bradbury and colleagues published in the journal in 2015, which focuses on recombinant antibodies.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics